Doxorubicin Completed Phase 2 Trials for Breast Cancer / Non-Hodgkin's Lymphoma (NHL) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00258960Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
NCT00129376Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients
NCT00365417Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
NCT00254592Neoadjuvant Treatment of Breast Cancer
NCT00128856Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients
NCT01008150Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer
NCT00005991Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
NCT00499083Paclitaxel, Cyclophosphamide, and Doxorubicin Followed by Autologous Dendritic Cells and Surgery With or Without Radiation Therapy and/or Hormone Therapy in Treating Women With Stage II or Stage III Breast Cancer
NCT03575520Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients
NCT00944047Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
NCT00499122NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
NCT01669239Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
NCT00665457Biomarkers in Women Receiving Chemotherapy and Celecoxib for Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00563953Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years
NCT00102219A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer
NCT00149214Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
NCT00136539Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
NCT00123929Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer
NCT00052351Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
NCT00007904Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
NCT00027885Phase II Bevacizumab + Tax In Advanced Breast Cancer
NCT00044993Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer
NCT00005800Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
NCT00006110Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer
NCT00005980Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
NCT00004906Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
NCT00003953Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
NCT00003992Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
NCT00004175Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer
NCT00004092Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00004237Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer
NCT00002679Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
NCT00003050Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
NCT00003035Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer
NCT00003352Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT02838225DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
NCT01205503Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
NCT01206881Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer
NCT01396655PET in Breast Cancer Receiving Neoadjuvant Chemotherapy
NCT02001519Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy
NCT00712881Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer
NCT00591851Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
NCT00546156Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
NCT00482391Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
NCT00960336Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer
NCT00394251Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
NCT00455533Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
NCT00365365Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
NCT00203502Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
NCT00201708Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
NCT00206466Biologic Correlative Taxotere/AC
NCT00193115Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer
NCT00193037Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
NCT00191789Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer
NCT00184002Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas
NCT00201318A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen